A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subjects with melanoma in complete clinical remission.
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
|Eligible Ages||18 Years and Over|
- - Willing and able to give written informed consent
- Histologic diagnosis of malignant melanoma, stages IIB-IV in radiologically confirmed
complete clinical remission without clinical evidence of disease
- At least 4 weeks since surgery prior to first dosing of study agent
- Required values for initial laboratory tests:
- Neutrophil count ≥ 1.0 x 10⁹/L
- Platelet count ≥ 80 x 10⁹/L
- Hemoglobin ≥ 10.0 g/dL
- Serum creatinine ≤ 2.0 x mg/dL
- AST/ALT ≤ 2.0 x upper limit of institutional normal
- Serum bilirubin ≤ 2.0 x upper limit of institutional normal
- No active or chronic infection with HIV, Hepatitis B, or Hepatitis C
- ECOG performance status of ≤ 2
- Life expectancy of ≥ 6 months
- Men and women, ≥ 18 years of age
Exclusion Criteria:- Serious illnesses, e.g., serious infections requiring antibiotics - Previous bone marrow or stem cell transplant - Study subjects with known chronic infection with HIV, hepatitis B or C.
- - Study subjects with known autoimmune disease [e.g. SLE, RA] who have had significant symptoms within the past 3 years.
- - Metastatic disease to the central nervous system - Other malignancy within 3 years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, cervical carcinoma in situ, or incidental or localized prostate cancer treated with prostatectomy or radiation therapy - Prior chemotherapy or tumor vaccine therapy - Radiation therapy or major surgery within 4 weeks prior to first dose of study agent - Concomitant treatment with systemic corticosteroids greater than physiologic doses.
- - Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent - Pregnancy or lactation.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 0: Exploratory study involving very limited human exposure to the drug to determine whether a drug is modulating its target.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
This is a Phase II open label, randomized two-arm study to evaluate the safety, tolerability, and immunogenicity of Poly-ICLC matured DCs as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides (ARM A; DC Vaccine) compared to Montanide® ISA-51 VG (ARM B; Montanide Vaccine), both with systemic administration of Poly-ICLC on days 1 and 2 in study subjects with melanoma in complete clinical remission but at high-risk for disease recurrence.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
New York University Langone Medical Center
New York, New York, 10016
Icahn School of Medicine at Mount Sinai
New York, New York, 10029